Harvard Bioscience (HBIO) Return on Capital Employed (2011 - 2026)

Harvard Bioscience (HBIO) has 16 years of Return on Capital Employed data on file, last reported at 0.16% in Q1 2026.

• On a quarterly basis, Return on Capital Employed rose 11240.0% year-over-year to 0.16% in Q1 2026; TTM through Mar 2026 was 0.16%, a 11240.0% increase from a year earlier, with the FY2025 full-year figure at 59.68%, down 5162.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 0.16%, up from 85.12% in the prior quarter.
• Over the last five years, Return on Capital Employed for HBIO reached as high as 1.69% in Q4 2023 and fell as low as 211.56% in Q2 2025.
• Historically, Return on Capital Employed has averaged 37.9% across 5 years, with a median of 3.68% in 2022.
• Across the five-year window, Return on Capital Employed sank 20695 bps in 2025 and jumped 11240 bps in 2026, its largest moves.
• Year by year, Return on Capital Employed stood at 5.64% in 2022, then surged by 130 bps to 1.69% in 2023, then slumped by 596 bps to 8.4% in 2024, then sank by 914 bps to 85.12% in 2025, then surged by 100 bps to 0.16% in 2026.
• Per Business Quant data, the three most recent Return on Capital Employed figures were 0.16% in Q1 2026, 85.12% in Q4 2025, and 204.0% in Q3 2025.